Brian Skorney

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) fell Thursday afternoon in reaction to a disappointing report on an early readout for its remdesivir therapy, but investors should not "give up on this drug," Baird analyst Brian Skorney said on CNBC's "Closing Bell." The...

Aimmune Therapeutics Inc (NASDAQ: AIMT) recently received FDA approval for its peanut allergy drug Palforzia.  The Aimmune Analyst Baird analyst Brian Skorney maintained an Outperform rating on Aimmune with a $64 price target. The Aimmune Thesis With NESTLE S A/S ADR (OTC: NSRGY)...

Aimmune Therapeutics Inc (NASDAQ: AIMT) announced late Friday that it received FDA approval for Palforzia, its oral immunotherapy to treat peanut allergy. The Aimmune Analysts Baird analyst Brian Skorney maintained an Outperform rating and $64 price target for Aimmune shares. RBC Capital...

Biogen Inc (NASDAQ: BIIB) shares gained more than 25% earlier this year when the company said it planned a regulatory filing for its Alzheimer's drug aducanumab following a new data analysis.  Ahead of the Dec. 5 presentation of aducanumab data at the Clinical Trials on Alzheimer'...

Gilead Sciences, Inc. (NASDAQ: GILD) reported after the market close Thursday with results that left investors uninspired.  The Analysts Morgan Stanley analyst Matthew Harrison maintained an Equal-weight rating on Gilead with a $75 price target. Baird analyst Brian Skorney maintained...

Aimmune Therapeutics Inc (NASDAQ: AIMT) shares have been on an extended downtrend since the start of 2018. This thinly traded, small-cap biotech is on the radar ahead of a key FDA panel meeting scheduled for Friday, Sept. 13. A briefing document posted on the FDA’s website Wednesday...

Gene therapy is an emerging therapeutic area, and Axovant Gene Therapies Ltd (NASDAQ: AXGT) is an attractive play on the sector, according to Baird. The Analyst Brian Skorney upgraded Axovant from Neutral to Outperform and lowered the price target from $16 to $13. The Thesis Axovant...

Biogen Inc (NASDAQ: BIIB) announced Monday a deal to buy gene therapy biotech Nightstar Therapeutics PLC (NASDAQ: NITE) for $800 million. The Analysts Baird analyst Brian Skorney maintained a Neutral rating on Biogen with a $348 price target. H.C. Wainwright analyst Andrew Fein reiterated a Buy...

The Street’s becoming increasingly — albeit reluctantly — bullish on Biogen Inc (NASDAQ: BIIB). “While we have all the enthusiasm that goes with catching a falling knife here, we believe BIIB shares are too ‘cheap’ to sit on the sidelines,” Baird Equity...

Even after Wednesday’s 31-percent run, a Baird analyst forecast 300-percent upside to Proteostasis Therapeutics Inc (NASDAQ: PTI). By the analyst's assessment, the market hasn’t fully appreciated the biotech’s PTI-428 candidate. The Rating Baird Equity Research analyst Brian...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has been in steady decline since July, and one analyst, though conceding the selloff from $500 was justified, said the Street’s taken it too far. The Rating Baird Equity Research analyst Brian Skorney upgraded Regeneron from Neutral to Outperform...

Ahead of Regeneron Pharmaceuticals Inc (NASDAQ: REGN)'s quarterly report, scheduled for Wednesday, Nov. 8, the company's shares won an upgrade. Regeneron shares fell beneath Baird's price target after an August downgrade, analyst Brian Skorney said in a Friday note. With better-than-...

Celgene Corporation (NASDAQ: CELG) stock plummeted 10 percent Friday after the company reported that its testing of GED-0301 for treatment of Crohn’s disease has failed to meet its efficacy targets. A handful of Wall Street analysts weighed in on Celgene stock following the news. Here’s...

After announcing the termination of its mongerson program for Crohn’s disease, Celgene Corporation (NASDAQ: CELG) is looking more and more unwell. “While the loss of one of the company's most advanced and high-profile pipeline programs is, in and of itself, disappointing, we believe...

Following the failure of Axovant Sciences Ltd (NASDAQ: AXON)'s late-stage MINDSET study, which evaluated its Alzheimer's treatment candidate intepirdine, Baird said its bull thesis is blown out. However, HC Wainwright said the setback is not the end of the world for the company. Baird...